19.05.2024, 1068 Zeichen

Valneva: Valneva, a specialty vaccine company, today reported further positive pivotal Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine. Following the initial analysis up to Day 29 post-vaccination, the most recent analysis of study VLA1553-321 evaluated the safety and immunogenicity six months (Day 180) after vaccination with a single dose of the vaccine. The Day 180 results confirm the initial positive immunogenicity and safety data Valneva reported previously, and are intended to support filing for potential label extension for use in adolescents aged 12 to 17 years. The data are also expected to support licensure of IXCHIQ^® in Brazil, which would be the first potential approval for use in endemic populations. Three marketing applications are currently under review by the European Medicines Agency, Health Canada and the Brazilian Health Regulatory Agency (ANVISA) with potential approvals in 2024.
Valneva: weekly performance: 21.88%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (13/05/2024)

Christian Drastil: Wiener Börse Plausch

Börsepeople im Podcast S16/21: Valerie De Icco-Streibel

Bildnachweis

Aktien auf dem Radar:Austriacard Holdings AG, Addiko Bank, Agrana, Semperit, Cleen Energy, Uniqa, Rosenbauer, UBM, Pierer Mobility, CA Immo, AT&S, Gurktaler AG Stamm, Kostad, Kapsch TrafficCom, Marinomed Biotech, Stadlauer Malzfabrik AG, Wolford, Polytec Group, Warimpex, Strabag, Amag, Zumtobel, Frequentis, Flughafen Wien, Oberbank AG Stamm, Palfinger, BKS Bank Stamm, Porr, RHI Magnesita, EVN, OMV.

---